InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $160.63M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 0.66M
Average 1.80M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +216.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +216.8% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +132.14% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $198.22M | $4.01 | Not rated | -2.7 | +12.98% |
Sutro Biopharma, Inc. NASDAQ:STRO | $162.83M | $9.82 | Not rated | -0.0 | -4.18% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -74.53% |
ImageneBio Inc NASDAQ:IMA | $39.39M | $3.47 | Not rated | -1.5 | -37.11% |
Kalaris Therapeutics Inc NASDAQ:KLRS | $37.49M | $1.58 | Not rated | -2.5 | -65.57% |
Context Therapeutics Inc. NASDAQ:CNTX | $16.61M | $0.18 | Not rated | -1.5 | -40.77% |
aTyr Pharma, Inc. NASDAQ:ATYR | $14.97M | $6.11 | Not rated | -0.7 | -21.25% |
Continue the stock analysis
Jump to another research area for this company.